A detailed history of Black Rock Inc. transactions in In8 Bio, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 57,080 shares of INAB stock, worth $14,270. This represents 0.0% of its overall portfolio holdings.

Number of Shares
57,080
Previous 28,204 102.38%
Holding current value
$14,270
Previous $33,000 45.45%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$0.85 - $1.68 $24,544 - $48,511
28,876 Added 102.38%
57,080 $48,000
Q1 2024

May 10, 2024

SELL
$0.95 - $1.69 $589 - $1,047
-620 Reduced 2.15%
28,204 $33,000
Q4 2023

Feb 13, 2024

SELL
$0.69 - $2.34 $612 - $2,077
-888 Reduced 2.99%
28,824 $39,000
Q3 2023

Nov 13, 2023

SELL
$0.92 - $1.74 $14,148 - $26,759
-15,379 Reduced 34.11%
29,712 $30,000
Q2 2023

Aug 11, 2023

BUY
$1.05 - $3.24 $13,116 - $40,474
12,492 Added 38.32%
45,091 $69,000
Q1 2023

May 12, 2023

BUY
$1.17 - $2.83 $1,249 - $3,022
1,068 Added 3.39%
32,599 $42,000
Q4 2022

Feb 13, 2023

BUY
$1.39 - $2.47 $11,366 - $20,197
8,177 Added 35.01%
31,531 $72,000
Q3 2022

Nov 14, 2022

SELL
$1.77 - $2.89 $9,011 - $14,712
-5,091 Reduced 17.9%
23,354 $47,000
Q2 2022

Aug 12, 2022

BUY
$2.02 - $4.68 $24,464 - $56,679
12,111 Added 74.15%
28,445 $65,000
Q1 2022

May 12, 2022

BUY
$2.76 - $4.6 $18,693 - $31,155
6,773 Added 70.84%
16,334 $54,000
Q4 2021

Feb 10, 2022

BUY
$4.39 - $8.55 $1,097 - $2,137
250 Added 2.68%
9,561 $42,000
Q3 2021

Nov 09, 2021

BUY
$6.71 - $10.0 $62,476 - $93,110
9,311 New
9,311 $64,000

Others Institutions Holding INAB

About IN8BIO, INC.


  • Ticker INAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 24,502,200
  • Market Cap $6.13M
  • Description
  • IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of...
More about INAB
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.